Initiator Pharma (INIT) Q2 2026 earnings summary

Executive summary

• Strategic focus shifted entirely to pudafensine, discontinuing IP2018 development to maximize value and commercial potential in vulvodynia and organic erectile dysfunction.

• Phase IIa clinical trial for pudafensine in vulvodynia is progressing as planned, with topline results expected by year-end 2026.

• Strengthened intellectual property position with new patents granted in Europe, Hong Kong, and Singapore, extending exclusivity into the mid-2040s.

• Board strengthened with the addition of Christina Lloyd, an expert in women's health.

Financial highlights

• No revenue generated in Q2 or H1 2026.

• Operating loss for Q2 2026 was TDKK 9,499, up from TDKK 3,844 in Q2 2025, reflecting increased R&D costs for the vulvodynia trial.

• Net loss for Q2 2026 was TDKK 9,483 (Q2 2025: TDKK 3,864); H1 2026 net loss was TDKK 21,034 (H1 2025: TDKK 6,517).

• Cash and cash equivalents at June 30, 2026 were TDKK 17,070, down from TDKK 26,245 at year-end 2025.

• Equity at June 30, 2026 was TDKK 8,511, with an equity ratio of 41%.

Outlook and guidance

• Topline results from the Phase IIa vulvodynia study expected by end of 2026.

• Current resources, including undrawn convertible facility, expected to fund operations through study completion and into 2027.

• Continued focus on advancing pudafensine, strengthening IP, and progressing partnering discussions.